Clinical Trial Data Release: Be Careful What You Wish For, Industry Exec Says
Executive Summary
Some advocates and researchers say that data availability could inform repurposing opportunities for products, but a GSK exec cautions that it could just as easily bring a flood of confusing information.
You may also be interested in...
Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes
US FDA contemplating how to match orphan designation process with drug development moving to molecularly-targeted therapies.
NIH Translational Science Center Gets Expanded Powers In Cures Bill
When NCATS was created, industry was wary of allowing Phase III trials; now sponsors embrace it.
Clinical Data Sharing Could Increase Research Costs, Industry Fears
NIH-funded investigators may direct money away from research to prepare their data for public release; some wonder whether grants should include the cost.